Answers are grounded in this paper and cite their sources.
Regulatory safety surveillance reports rare secondary T-cell cancers in patients receiving CAR-T therapy, highlighting the need for ongoing adverse event monitoring.
As of December 31, 2023, the FDA had become aware of 22 cases of T-cell cancers that occurred after treatment with CAR-T products. For now, such cancers appear to be relatively rare adverse events.
No takes yet. Share an insight, caveat, or question.
Verdun et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: